India Pharma Outlook Team | Wednesday, 17 June 2026
.jpeg "Hyderabad Emerges as Pharma R&D Hub with Neuland's $20M Bet")
Hyderabad is steadily consolidating its position as India’s leading pharmaceutical innovation hub, with fresh investments reinforcing the city’s role in early-stage drug development and process research.
The latest move comes from Neuland Laboratories, which plans to invest $20 million to set up a new process development facility at its Genome Valley campus.
The facility, spread across 135,000 square feet, will be developed in phases and is expected to be fully operational by October 2026. Unlike conventional manufacturing expansions, this investment is focused on strengthening research and development capabilities, specifically in process chemistry, scale-up science, and advanced drug development workflows.
Genome Valley, already home to a dense cluster of biotech firms, contract research organizations, and manufacturing units, has increasingly become a center for high-value scientific work rather than just production.
Neuland’s expansion fits into this shift, adding depth to the ecosystem by focusing on the transition phase between laboratory discovery and commercial manufacturing.
At the core of the new facility is a process development laboratory integrated with a non-GMP kilo lab, designed to simulate large-scale chemical reactions at a smaller scale. This capability is critical for pharmaceutical companies looking to move molecules from discovery to manufacturable products efficiently.
The kilo lab will be equipped with 20–250 liter all-glass reactors, cryogenic systems, and multiple filtration setups, allowing scientists to replicate complex production conditions in a controlled environment. This setup enables early identification of manufacturing challenges, reducing risks and timelines in later stages.
The center will house five dedicated peptide laboratories and three purification labs, reflecting the growing importance of peptide-based therapeutics in global drug pipelines. In addition, specialized zones will focus on process engineering, polymorph studies, process safety, and advanced flow chemistry areas that are becoming increasingly important in modern pharmaceutical development.
Once completed, the facility will expand Neuland’s process development team to over 500 scientists, significantly increasing its capacity to handle complex, multi-stage projects. According to the company, the investment is primarily directed at equipping the facility rather than constructing new infrastructure, signaling a focus on high-end capabilities rather than physical scale alone.
This approach aligns with evolving client expectations in the contract development and manufacturing (CDMO) space, where early-stage collaboration and parallel development are becoming critical. By enabling clients to gain manufacturability insights at an earlier stage, the facility is designed to compress development timelines and improve efficiency.
Leader's Thoughts: Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections
Neuland’s investment is part of a broader trend that is reshaping Hyderabad’s pharmaceutical landscape. The city is no longer just a manufacturing base; it is increasingly becoming a hub for innovation, driven by a combination of skilled talent, established infrastructure, and a mature industry ecosystem.
Genome Valley plays a central role in this transformation. Its proximity to research institutions, availability of specialized talent, and integration of R&D with manufacturing capabilities make it an attractive destination for global pharmaceutical companies. The presence of CDMOs, biotech startups, and large pharma firms in a single cluster creates synergies that accelerate innovation.
Another key factor is the shift in global pharmaceutical strategies. Companies are increasingly outsourcing complex development work to specialized partners, particularly in areas such as process chemistry and scale-up. Hyderabad, with its growing expertise in these domains, is well positioned to capture this demand.
The rise of advanced therapies, including peptides and complex generics, is also driving the need for sophisticated development infrastructure. Facilities like Neuland’s are designed to meet these requirements, enabling India to move beyond traditional generics manufacturing into higher-value segments of the pharmaceutical value chain.
As more investments flow into R&D-focused infrastructure, Hyderabad’s role in the global pharma ecosystem is likely to expand further. The city is evolving into a critical node where scientific research, process development, and manufacturing converge, making it not just a production hub but a center for innovation-led growth in pharmaceuticals.
